ClinicalTrialsFinder

Metastatic/Locally Advanced Poorly Differentiated NEC Clinical Trials in Villejuif

1 recruitingVillejuif, France

Showing 1–1 of 1 trials

Recruiting
Phase 2

Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)

Metastatic/Locally Advanced Small-Cell Lung CancerMetastatic/Locally Advanced Poorly Differentiated NECMetastatic/Locally Advanced High-grade MTC
Gustave Roussy, Cancer Campus, Grand Paris40 enrolled1 locationNCT07016230